Kornimate/medical-research-clean huggingface dataset:
using near infra-red spectroscopy to measure tissue perfusion in patients receiving coronary artery bypass graft surgery

Conditions: Coronary Artery Disease

Summary: near infra-red spectroscopy (nirs) was used to measure the tissue perfusion of the cerebral cortex with two noninvasive adhesive patches in recent years. this study is designed to compare the regional tissue perfusion of different body areas in patients receiving coronary artery bypass surgery under general anesthesia. the nirs data will also be used to compare with other routine physiological monitors in the surgery.

study design: prospective observational study target number of participants: to recruit 50 patients into this study. patient selection: 1. patients scheduled for elective coronary artery bypass surgery. 2. the american society of anesthesiologists physical status classification system(asa) class i\~iii 3. age ≧20 y/o, ≦75 y/o exclusion criteria: 1. asa class iv 2. current skin lesion over the sites where the nirs patches are designed to be attached. 3. patients received cardiopulmonary bypass during the surgery. 4. patients with previous history of allergy to the nirs patches. study method: after the induction of anesthesia, four nirs patches are attached to the patients on the following sites: 1. biceps brachii muscle area 2. gastrocnemius muscle area 3. posterior side of neck 4. central part of the forehead the four non-invasive nirs patches are only to measure the tissue oxygen saturation and have no other physiological effects on the participants. the data will be collected every 5 minutes until the surgery is completed. the data from other routine monitors used during the surgery (including hear rate, blood pressure, and mixed venous saturation) will also be used to compare with the data from nirs.

Eligibility criteria:
inclusion criteria: * age ≧20 years old, ≦75 years old * patients scheduled for elective coronary artery bypass surgery * asa class i\~iii exclusion criteria: * patients scheduled for cardiopulmonary bypass * allergy for nirs

Keywords: near infra-red spectroscopy, coronary artery bypass grafting
effect of delayed cord clamping in preterm neonates with placental insufficiency

Conditions: Preterm Infant; Placental Insufficiency; Placental Transfusion

Summary: to investigate the effect of delayed cord clamping (dcc) on hematopoietic progenitor cells (hpcs), hematological parameters including haemoglobin concentration and hematocrit value in premature infants (34 weeks gestational age or less) with placental insufficiency.we hypothesized that preterm infants with placental insufficiency underwent ddc could have better hematologic parameters and hematopoietic progenitor cells compared to immediate cord clamping.

• a prospective randomized controlled study will be performed on preterm infants 34 weeks gestational age or less with placental insufficiency, and those without placental insufficiency where dcc will be performed in both groups. a third group of preterm with placental insufficiency and immediate cord clamping will be performed as a control.

Eligibility criteria:
inclusion criteria: * preterm neonates \< 34 weeks gestational age exclusion criteria: * vaginal bleeding due to placental abruption or tears multiple pregnancies suspected major fetal anomalies suspected chromosomal aberration maternal drug abuse hydrops fetalis preterm who needed major resuscitative measures

Keywords: delayed cord clamping preterm infant placental insufficiency intrauterine growth restriction
dispersion stability

Conditions: Atrial Fibrillation

Summary: to assess the acute efficacy of ablation of the most stable vx1 areas (levels 2 and 3) in terms of the rate of acute af termination. identify the spatial distribution of dispersion stability levels based on vx1. document the rate of adverse events. to assess the long-term efficacy of ablation of the most stable vx1 areas in terms of the absence of documented arrhythmias during a 12-month follow-up.


Eligibility criteria:
inclusion criteria: 1. patients 18 years of age or older candidates with persistent or long-standing persistent af with documentation of (ecg, holter, physician's letter): * af duration of ≥ 3 months and ≤ 5 years or * 1 effective cardioversion followed by af recurrence lasting ≥ 3 months 2. continuous anticoagulation with warfarin (inr 2-3) or noac for \> 4 weeks prior to ablation 3. patients must be able and willing to provide written informed consent to participate in the clinical trial 4. maximum of 50% of patients (13 patients) in persistent af \ 30% of long-standing persistent af ≥ 12 months) 5. being affiliated to a social security scheme or beneficiary of such a scheme exclusion criteria: 1. paroxysmal and short-standing persistent af \< 3 months 2. severe obesity (bmi \> 45) 3. la thrombus on transesophageal echocardiography (tee) prior to procedure 4. contraindications to anticoagulation (heparin, warfarin or noac) 5. patients who are or may potentially be pregnant 6. any cardiac surgery within the past 2 months (60 days) (includes pci) 7. myocardial infarction within the past 2 months (60 days) 8. history of blood clotting or bleeding abnormalities 9. documented thromboembolic event (including tia) within the past 12 months (365 days) 10. awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days) 11. unstable angina within the past month 12. acute illness or active systemic infection or sepsis (including covid 19) 13. enrollment in an investigational study evaluating another device, biologic, or drug 14. presence of intramural thrombus, tumor or other abnormality or condition that precludes vascular access, or manipulation of the catheter 15. life expectancy or other disease processes likely to limit survival to less than 12 monthslife expectancy or other disease processes likely to limit survival to less than 12 months 16. acute covid-19 infection (fever and/or biological inflammatory syndrome, and positive test documented) 17. patient protected (guardianship or curatorship), or deprived of liberty by a judicial or administrative decision; 18. person subject to a safeguard measure.
single arm study of induction chemoradiotherapy combined with surgery in the treatment of locally advanced snmm

Conditions: Mucosal Melanoma; Sinonasal Melanoma

Summary: sinonasal mucosal melanoma (snmm) is a very rare tumor, and snmm is highly aggressive in nature, with a 5-year survival rate of about 20\~30%. most patients underwent local recurrence and distant metastasis within one or two years of treatment. there is no unified standard for the treatment of snmm.the principle of treatment for surgically resectable stage t3 and partial t4 snmm is complete resection of the primary tumor, combined with postoperative radiotherapy. while locally unresectable snmm has a poorer prognosis, lower incidence, fewer clinical data have been reported. this study will explore the role of preoperative radiotherapy and chemotherapy in improving the 2-year os rate, loco-regional control rate and distant metastasis rate.


Eligibility criteria:
inclusion criteria: 1. age over 18 years old; 2. pathologically confirmed with sinonasal mucosal melanoma; 3. eligible for assessment by enhanced contrast computed tomography scan or magnetic resonance imaging (mri); 4. t4n0-1m0 according to the 8th edition american joint committee on cancer (ajcc) staging system, and breaks through the natural anatomical boundaries of orbital fascia or dura mater; or 2) any tumor stage, with retropharyngeal node metastasis. unresectable tumor after multi-disciplinary team (mdt) discussion. 5. eastern cooperative oncology group (ecog) score between 0 to 2; 6. no distant metastasis; 7. adequate organ function; 8. sign the informed consent forms. exclusion criteria: 1. there is evidence or suspicious of distant metastasis on clinical examination or imaging examination; 2. suffered from uncontrolled concurrent diseases that may interfere with treatment; 3. suffered from another malignant tumor or multiple primary tumors at the same time within 5 years (excluding fully treated basal cell or squamous cell skin cancer, cervical cancer in situ, etc.); 4. with surgical contraindications: severe cardiopulmonary disease, coagulation dysfunction, etc; 5. with and conditions that interfere with patient compliance or safety; 6. with severe mental or neurological diseases; 7. uncontrolled active infection diseases; 8. pregnant or breastfeeding women; 9. patients without personal freedom or independent civil capacity; 10. other situations that are not suitable.

Keywords: sinonasal mucosal melanoma inductive radiotherapy chemotherapy overall survival
daily or weekly cladribine in treating patients with hairy cell leukemia

Conditions: Leukemia

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. it is not yet known if giving cladribine once a day is more effective than giving cladribine once a week in patients with hairy cell leukemia. purpose: randomized phase iii trial to compare the effectiveness of cladribine given once a day to cladribine given once a week in treating patients with hairy cell leukemia.

objectives: * compare the acute hematotoxicity and infection rate with daily and weekly administration of cladribine in patients with hairy cell leukemia. outline: this is a randomized, multicenter study. patients are randomized to one of two treatment arms. * arm i: patients receive daily subcutaneous bolus injections of cladribine (2-cda) for 5 days (standard dose). * arm ii: patients receive weekly subcutaneous bolus injections of 2-cda for 5 weeks. patients showing complete or partial remission at evaluation on day 71 of the first treatment course do not receive any further treatment until relapse or disease progression is evident. patients showing minor or no response on day 71 of the first treatment course receive a subsequent course of standard dose 2-cda. patients are followed every 3 months for 2 years, then every 6 months thereafter. projected accrual: a total of 120 patients will be accrued for this study within 4 years.

Eligibility criteria:
disease characteristics: * histologically confirmed classic form or prolymphocytic variant hairy cell leukemia (hcl) * newly diagnosed hcl or progressive disease after prior treatment patient characteristics: age: * 18 and over performance status: * nci 0-2 life expectancy: * at least 3 months hematopoietic: * not specified hepatic: * bilirubin no greater than 2.0 mg/dl renal: * creatinine no greater than 2.3 mg/dl other: * hiv negative * not pregnant * no other prior or concurrent malignancy except carcinoma in situ of the cervix or basal or squamous cell carcinoma of the skin prior concurrent therapy: * at least 4 weeks since any prior therapy and recovered biologic therapy: * not specified chemotherapy: * no concurrent cytoreductive therapy * no prior cladribine endocrine therapy: * not specified radiotherapy: * not specified surgery: * not specified

Keywords: untreated hairy cell leukemia progressive hairy cell leukemia, initial treatment prolymphocytic leukemia
comparison of the effect of an ongoing treatment with alendronate or a drug holiday on the fracture risk in osteoporotic patients with bisphosphonate long term therapy

Conditions: Osteoporosis

Summary: the purpose of this study is to evaluate the efficacy and safety of bisphosphonates in long term treatment of osteoporosis.

is a continued treatment with alendronate for another two years after a preceding therapy with bisphosphonates of at least four years able to reduce the incidence of new osteoporotic fractures in patients at high fracture risk compared to a therapy-free interval?

Eligibility criteria:
inclusion criteria: * postmenopausal women or men \> 60 years * dxa t-score at lumbar spine, total hip or femur neck \<-2,0 before the start of the bisphosphonate therapy or at baseline or at least one low trauma vertebral fracture grade 2-3 or multiple low trauma vertebral fractures independent of bone mineral densitiy * pretreatment with bisphosphonates for at least four years * risk for hip and vertebral fractures min. 30% according to dvo-guideline for osteoporosis 2009 * signed informed consent exclusion criteria: * other pharmacological treatment of osteoporosis during the last 48 months * other bone diseases * malabsorption syndromes * renal insufficiency with a calculated creatinine clearance \< 35 ml/min * diseases of the esophagus, delayed esophageal clearance * uunability to realise the intake instructions * hypocalcemia

Keywords: osteoporosis osteoporotic fractures bisphosphonate pretreatment with bisphosphonates
understanding the natural history early in the course or presentation of friedreich ataxia

Conditions: Friedreich Ataxia; Rare Diseases

Summary: multicenter, prospective, observational natural history and outcome measure study of children and young adults with friedreich ataxia.

a multicenter, prospective, observational natural history and outcome measure study of children and young adults with friedreich ataxia to further understand the disease features and progression and inform and enable future clinical trials in children with fa. the study, understanding the natural history early in the presentation of friedreich ataxia: evaluating new clinical outcome assessments in children with friedreich ataxia to facilitate clinical trial design (early-fa), evaluates disease features specific to children and novel biomarkers and outcome measures which leveraging existing clinical research infrastructure and data collection from an established natural history study, unifai.

Eligibility criteria:
inclusion criteria for participants with fa: 1. genetic diagnosis of friedreich ataxia 2. ages 4-21 years at enrollment 3. enrollment in the unifai study and ability to have simultaneous visits for both unifai and early-fa 4. informed consent must be obtained for all participants: 1. for underage participants, they and the parent/ legally authorized representative have to sign the informed consent form, child assent (if applicable) 2. persons who are not legally competent require the informed consent of their legally authorized representative inclusion criteria for control participants: 1. ages 4-21 years at enrollment 2. matching criteria to an enrolled participant with fa (age, sex and educational status) 3. informed consent must be obtained for all participants: 1. for underage participants, they and the parent/ legally authorized representative have to sign the informed consent form, child assent (if applicable) 2. persons who are not legally competent require the informed consent of their legally authorized representative exclusion criteria for participants with fa: 1. diagnosis of non-fa medical or other condition that in the opinion of the investigator would interfere with the conduct and assessments of the study or be confounding and contraindication to participation. 2. pregnant female participants 3. unable to provide informed consent. exclusion criteria for control participants: 1. family risk for fa with unknown status 2. diagnosis of a medical condition that in the opinion of the investigator could be confounding and contraindication to participation 3. unable to provide informed consent
our emergency fasciotomy and amputation experiences

Conditions: Amputation; Compartment Syndromes; Earthquake

Summary: earthquakes are natural disasters that threaten human life and cause loss of life and property in a very short time. in our country, where a large part of the population faces the risk of earthquakes, unfortunately, destructive earthquakes that put the country at a disadvantage in social and economic terms are frequently experienced.

on 6 february 2023, two major earthquakes with a magnitude of 7.7 at 04:17 and 7.6 at 13:24 local time occurred in kahramanmaraş. in southern turkey and northern syria, 11 cities and approximately 14 million people were affected. according to the latest official data, at least 50,783 deaths, more than 122,000 injuries, and major damage occurred. the triage, treatment, and management of the injured was a challenging administrative task. the injured were treated in many centres throughout the country. in our hospital, all relevant units provided multidisciplinary service to our earthquake victims. superficial injuries, fractures, open wounds due to high-energy trauma, compartment syndrome due to compression, and crush injuries are frequently encountered after earthquakes, and patients are usually exposed to multiple traumas. the most common injuries associated with earthquakes are extremity injuries and crush syndrome. first and emergency intervention, including basic life, is usually performed in the disaster area. emergency surgical procedures such as amputation and fasciatomy may be required for patients with compartment syndrome. the planning of all these surgeries and the follow-up and evaluation of patients require a multidisciplinary approach. in this study, we planned to retrospectively investigate the anaesthesia management in emergency fasciatomy and amputation surgeries performed in the orthopaedic operating room of patients who were transferred to or admitted to the 3rd level city hospital during the earthquake disaster on 6 february. we found that anaesthesia data on earthquake victims in the literature were insufficient. we aimed to share our experiences in order to provide guidance in terms of anaesthesia management in possible future disasters.

Eligibility criteria:
inclusion criteria: * 6 february 2023 earthquake victims who applied to our clinic within 2 months after the earthquake and received anaesthesia and underwent emergency fasciotomy and amputation in the orthopaedic operating room, regardless of gender, aged 18 years and over. exclusion criteria: * patients who are not earthquake survivors and under 18 years of age and who have undergone surgery other than fasciatomy or amputation will not be included.

Keywords: fasciotomy amputation earthquakes 6 february 2023 kahramanmaraş turkey earthquakes compartment syndromes
impact of breakfast composition on glycemic and incretin responses in individuals with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: this study examined the effect of a high protein or high carbohydrate breakfast on the glucose and insulin response following the breakfast meal, as well as the subsequent response following the lunch meal.

twelve habitual breakfast consumers with type 2 diabetes (t2d) were recruited for the study. they completed two, 7-day conditions in random order with a minimum of a 7-day washout period between study days. they consumed either a high protein (pro) or high carbohydrate (cho) breakfast for 6 days of acclimatization, and on the seventh day, they reported to the lab at 0700 hours following a \~12 hour overnight fast and underwent forearm catheterization before a baseline blood draw. the participants consumed the respective breakfast at \~0730 hours. four hours post-breakfast, subjects consumed a standard lunch meal. blood samples were taken continuously throughout the 8-hour test day.

Eligibility criteria:
inclusion criteria: * 21-55 y of age * body mass index (bmi) between 30-40 kg/m2 * weight stable for the prior 6 months * non-smokers * minimal alcohol consumption (\< 2 drinks per day) * type 2 diabetic (diagnosed ≥ 2 y) * a fasting glucose level above 120 mg/dl * hba1c between 6.5-9.0% exclusion criteria: * insulin * β-blockers * glp-1 agonists (e.g. exenatide) * dipeptidyl peptidase (dpp) inhibitors * weight loss * using weight-loss medications * pregnant or lactating

Keywords: glp-1 gip second meal phenomena type 2 diabetes
diabetes in pregnancy and pregnancy outcomes

Conditions: Diabetes Mellitus in Pregnancy; Diabetes, Gestational

Summary: to compare the clinical, glycemic profile and therapy as well as pregnancy complications and infant mortality among diabetic mothers in indonesia.

pregnancy is a diabetogenic state with increasing burden on the mother's metabolism. insulin resistance is often found during pregnancy leading to a compensatory increase in pancreatic β-cell response and eventually hyperinsulinemia. undiagnosed and untreated diabetes in pregnancy have been shown to be linked with numerous comorbidities and complications to both mother and foetus. this study aims to compare the clinical, glycemic profile along with comorbidities, management and outcomes of diabetic mothers. pregnant mothers with gestational and pregestational diabetes diagnosed under the icd-10 coding of o24 were included in this study. the inclusion criteria was all patients with primary diagnosis of o24, have visited the clinic at least twice with a complete record of glycemic profile, management and fetal outcomes.

Eligibility criteria:
inclusion criteria: * clinical and laboratory diagnosis of diabetes in pregnancy (gestational and pregestational diabetes) * mothers must have visited the clinic at least twice throughout their pregnancy, at least one at the first trimester and one at the third trimester exclusion criteria: * pregnancy is still undergoing * incomplete record of glycemic profile, management and fetal outcomes

Keywords: diabetes mellitus in pregnancy gestational diabetes pregnancy outcomes
platelet rich fibrin in the treatment of palatal wounds

Conditions: Gingival Recession

Summary: in this study it will be investigated the usefulness of platelet-rich fibrin (prf) on in the epithelialized connective tissue graft palatal donor site healing acceleration and in the patient's morbidity reduction. forty patients, with at least one gingival recession will be treated by a coronally advanced flap (caf) with connective tissue graft(ctg) resulting from the de-epithelialization of a free gingival graft. in the test group (20 patients) a quadruple layer of prf membrane will be placed over the palatal wounds; conversely, the control group patients will be treated by an absorbable gelatin sponge. patients will be monitored at 1, 2, 3 and 4 weeks after surgery for the complete re-epithelialization of the palatal wound (cwe), the alteration of sensibility (as) around the wound area, the post-operative discomfort (d), and the changes of feeding habits (cfh) by a visual analogic scale (vas) evaluation. furthermore, the analgesics consumption and the existence of delayed bleeding from the palatal wound (dwb) during the first post-operative week will be assessed.


Eligibility criteria:
inclusion criteria: are as follows: * to have a single gingival recession to be treated by a mucogingival surgery intervention * to be in good systemic health * to have a good oral hygiene exclusion criteria: * no systemic diseases; no coagulation disorders; no medications affecting periodontal status in the previous 6 months; no pregnancy or lactation; * no smoking habits; * no periodontal surgery on the experimental sites; * no inadequate endodontic treatment * no tooth mobility at the site of surgery

Keywords: connective tissue grafts wound healing biomaterials pain clinical trials mucogingival surgery